SOURCE: AxoGen, Inc.

AxoGen, Inc.

January 09, 2015 07:15 ET

AxoGen, Inc. CMO Jill Schiaparelli and Oral Maxillofacial Surgeon Dr. Shahrokh Bagheri to Discuss Nerve Injury and Repair Options Live on iHeart Business Talk Radio HealthTech Talk Live -- January 10, 2015

Live Interview Airs on HealthTech Talk Live, Hosted by Ben Chodor, 3:00pm ET/12:00pm PT/2:00pm CT

ALACHUA, FL--(Marketwired - Jan 9, 2015) - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company dedicated to peripheral nerve repair, announced today that Chief Marketing Officer Jill Schiaparelli will be interviewed live on iHeart Radio's debut episode of HealthTech Talk Live hosted by Ben Chodor and broadcast nationwide on iHeart Radio/ Clear Channel Atlanta Studios - 640 WGST AM this Saturday at 3:00 pm ET. In this exclusive double-segment interview, Ms. Schiaparelli will discuss AxoGen's portfolio of peripheral nerve repair solutions that offers alternatives to patients who require surgical repair of injured peripheral nerves. She will be joined by oral and maxillofacial surgeon and trigeminal nerve repair expert Dr. Shahrokh Bagheri, Chair of Oral and Maxillofacial Surgery at Northside Hospital in Atlanta, to talk about the impact of oral nerve injuries on patients.

Date: January 10, 2015 
Start Time: 3:00pm ET | 12:00pm PT | 2:00pm CT (U.S.)
Network: iHeart Radio / Clear Channel
Station: 640 WGST AM
Show: HealthTech Talk Live
Host: Ben Chodor
Live Stream: Click Here

About AxoGen, Inc.
AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen's portfolio of regenerative medicine products is available in the United States, Canada and several European countries and includes Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

To learn more about AxoGen and to sign up for news alerts, visit www.AxoGenInc.com.

About Chief Marketing Officer Jill F. Schiaparelli:
Jill Schiaparelli joined the AxoGen leadership team in February 2012 and oversees the business strategy, marketing, analytics, and patient awareness functions. Jill's passion is bringing technologies to the market that will make a profound difference in the lives of patients.

Jill brings to AxoGen more than 20 years of global business success in the medical device, biosurgery, and investment banking industries with leadership roles in commercial strategy, marketing and new product development. She has worked with major healthcare companies such as Johnson & Johnson and Baxter as well as high-growth companies such as ApaTech (UK) and now AxoGen. Jill also founded her own consulting business aimed at helping young companies bring high potential technologies to market.

About Shahrokh C. Bagheri, DMD, MD, FACS
Dr. Bagheri is the Chair of Oral and Maxillofacial Surgery at Northside Hospital of Atlanta, and serves as a clinical faculty at both Georgia Health Sciences University and Emory University, where he is involved in resident education. He is an internationally recognized surgeon and has published over 35 articles and 25 book chapters, and 2 textbooks including "Clinical Review of Oral and Maxillofacial Surgery" and "Current Therapy in Oral and Maxillofacial Surgery."

He received his DMD from Harvard University (cum laude, class marshall), and MD from Emory University, where he also completed his residency in oral and maxillofacial surgery and internship in General Surgery. He obtained his fellowship training in Cranio-Maxillofacial Trauma and Reconstruction. His particular interests include, implant surgery, facial cosmetic surgery, trauma, and reconstructive maxillofacial surgery. He is one of few surgeons in the United States that is trained in microneurosurgical repair of peripheral trigeminal nerve injuries with extensive publications on this topic. He is also one of three oral and maxillofacial surgeons in Georgia that qualifies for fellowship in prestigious American College of Surgeons (FACS). Dr Bagheri has lectured nationally and internationally on a variety of topics in facial surgery. He is currently in the editorial board of the Journal of Oral and Maxillofacial Surgery, and serves as peer reviewer of several other surgical journals.

About iHeart Radio/Clear Channel
Clear Channel's Media and Entertainment division has 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia.

About HealthTech Talk Live Show
HealthTech Talk Live broadcasts live weekly on iHeart Radio / Clear Channel nationwide from 640 WGST AM Atlanta, 3:00pm - 4:00pm ET every Saturday. Host Ben Chodor interviews the front-page emerging health tech innovators and titans about the latest in digital health technology, human ingenuity, bio-tech medical advancements and health tech capital market trends. Learn how the experts use risk management techniques and clinical trials to build fully diversified portfolios and what it takes to put up big board earnings from making people healthier. It's a fast moving, high-energy show... shift your thinking and join us as we deliver "tomorrow's ideas today" on iHeart Radio and Clear Channel's HealthTech Talk Live.

Cautionary Statement Concerning Forward-Looking Statements
This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", "will" variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our product development and product potential. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information